CN101658523A - New application of clofazimine for curing tuberculosis - Google Patents
New application of clofazimine for curing tuberculosis Download PDFInfo
- Publication number
- CN101658523A CN101658523A CN200910131770A CN200910131770A CN101658523A CN 101658523 A CN101658523 A CN 101658523A CN 200910131770 A CN200910131770 A CN 200910131770A CN 200910131770 A CN200910131770 A CN 200910131770A CN 101658523 A CN101658523 A CN 101658523A
- Authority
- CN
- China
- Prior art keywords
- clofazimine
- group
- tuberculosis
- mice
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a new application of clofazimine for curing tuberculosis. The clofazimine is 10-(p-chlorophenyl)-2,10-dihydro-3-(p-chlorobenzene amino)-2-isopropylimidophenazine; the inventionalso discloses a method for preparing various pharmaceutical preparations such as soft capsules, tablets, capsules, drop pills and injections and the like by taking the clofazimine as the raw material for medicine; and a large number of tests show that the medicine has the action of curing tuberculosis and is safe and effective in clinical use.
Description
Invention field
The present invention relates to a kind of new purposes of medicine, particularly a kind of new medicine use of clofazimine.
Technical background
Tuberculosis is the chronic infectious disease that tubercule bacillus causes, has the population that accounts for the world 1/3 to infect tulase approximately at present.China's tuberculosis epidemic situation also is spreading trend, has characteristics such as prevalence height, resistant rate height, is one of the high burden of global tuberculosis country.
Clofazimine is 10-(right-chlorphenyl)-2, and 10-dihydro-3-(right-chlorobenzene the amino)-different tetrahydroform base of 2-azophenlyene presses dry product and calculates, and contains C
27H
22Cl
2N
4Must not be less than 98.0%, former name is a clofazimine, and clofazimine is brownish red or crystallization russet or crystalline powder; Odorless.The agent of chlorine method is bright to be antileprotic, leprosy bacillus, mycobacterium buruli is had suppress and killing action, has antiinflammatory action in addition, all effective to treatment and prevention II type lepra reaction nodositas and erythema multiforme etc.Its antibacterial action may combine with its DNA by disturbing the nucleic acid metabolism of leprosy bacillus, suppresses to rely on the RNA polymerase of DNA, stops the synthetic of RNA, thereby suppresses the synthetic of bacterioprotein, brings into play its antibacterial action.
Summary of the invention
The objective of the invention is to disclose a kind of medicine and be used for the treatment of new purposes lungy.
The present invention seeks to be achieved through the following technical solutions:
Medicine clofazimine of the present invention is 10-(right-chlorphenyl)-2, and 10-dihydro-3-(right-chlorobenzene the amino)-different tetrahydroform base of 2-azophenlyene presses dry product and calculates, and contains C
27H
22Cl
2N
4Must not be less than 98.0%.
Press practice of pharmacy, medicine clofazimine of the present invention is prepared into the various clinical pharmaceutical dosage form as the treatment tuberculosis, comprises soft gelatin capsule, tablet, capsule, soft capsule, drop pill, honeyed pill, pill, granule, soft extract with bee honey agent, slow releasing preparation, quick releasing formulation, controlled release preparation, oral liquid or ejection preparation.
Medicine of the present invention is a kind of phenazine dyes, suppresses the effect that mycobacterium grows by combining with the DNA of mycobacterium to suppress to transcribe to produce; Its another one important function is to share with beta-interferon, can recover the effect of cytophagy and bactericidal activity, thereby becomes cytophagous exciting agent, belongs to the part of immunization therapy.
Following experimental example and embodiment are used to further specify but are not limited to the present invention.
Experimental example 1 clofazimine is treated pharmacodynamic experiment lungy
1, experiment purpose: the observation clofazimine (clofazimine, CLF) against mycobacterium tuberculosis activity in external and body is for clinical practice provides foundation.
2, experiment material
Bacterial strain: mycobacterium tuberculosis H
37R
V(ATCC27294) this research department preserves bacterial strain; 30 strain substance of medicines-resistant branched tubercle bacillus clinical separation strains are national tuberculosis Reference Lab and preserve bacterial strain.
Reagent: culture medium: take by weighing 7H9 culture medium (U.S. Difico company) 4.7g, be dissolved in the 900ml distilled water, add 2.0ml glycerol, 121 ℃ of high pressure 10min, the nourishing additive agent albumin dextrose catalase of adding 0.1 volume fraction before to be used (albumin dextrosecatalase, ADC).ALMA indigo plant (Alamar blue); Britain Setotec company product, 4 ℃ keep in Dark Place.Dimethyl sulfoxide (DMSO) analytical pure, Chengdu chemical reagent factory product.
Animal: SPF level 6-8 age in week, female BALB/C mice was 36, and body weight is 18-20g, available from Capital University of Medical Sciences's Experimental Animal Center.
Medicine: isoniazid (INH), rifampicin (RFP) are U.S. Sigma company product; Clofazimine is that the Nanjing pharmaceutical Co. Ltd of setting up one's own business is so kind as to give.
3, experimental technique
(1) MIC measures; 200 μ l aquesterilisa are added in each hole of aseptic 96 orifice plate surroundings, prevent the composition evaporation in the incubation mesopore.Make initial concentration with DMSO or sterile purified water dissolved substance, be diluted to required concentration, add aseptic 96 orifice plates, 100 μ l, measure H with 7H9 culture medium (not containing twecn80)
97R
VEach medicine final concentration of MIC is respectively: INH:0.0125,0.025,0.05,0.1,0.2,0.4 μ g/ml; RFP:0.0125,0.025,0.05,0.1,0.2,0.4 μ g/ml; CLF:0.03,0.06,0.12,0.24,0.48,0.96,1.92 μ g/ml.Mensuration is respectively each medicine final concentration of substance of medicines-resistant branched tubercle bacillus clinical separation strain MIC: INH:1,5,10,20,40 μ g/ml; RFP:1,5,10,20,40 μ g/ml; CLF:0.06,0.12,0.24,0.48,0.96,1.92,3.84 μ g/ml.Choose H
37R
VMake bacteria suspension with the culture of the anti-multiple medicines clinical isolates of 30 strains strain, be inoculated in the 7H9 culture medium that contains 0.05%tween80,10%ADC, in 37 ℃ of static cultivation 1-2 weeks, growing to turbidity is that MoFarland 1.0 (is equivalent to 10
7CFU/ml) time, the dilution back added each hole 100 μ l in 1: 20, and the final concentration of bacterium liquid is 10
6CFU/ml.Every plate is all established 2 growth control holes that do not contain antimicrobial drug, and 96 orifice plates are hatched in 37 ℃.The mixed liquor that adds growth control hole 20 μ l 10 * Alamar blue and 5%t,wee,n80 50 μ l behind the 7d, hatch 24h for 37 ℃, if color becomes pink colour from blueness, the Alamar blue and the tween80 mixed liquor that then in the hole of each experiment medicine, add above-mentioned amount, hatch the color that 24h writes down each hole for 37 ℃, blue Kong Weiwu growth, pink hole is for there being growth.MIC is defined as the lowest concentration of drug that stops change color (becoming pink from blueness).
(2) foundation of mice tuberculosis model and treatment: choose mycobacterium tuberculosis H
37R
VIt is (5 * 10 that the culture in 2-3 week is made concentration
5) bacteria suspension of CFU/ml, 36 female BALB/C mice tail vein injection 0.2ml/ only, infection dosage 10
5CFU/ only.Dissected 6 mices on the 2nd day so that the basic value that spleen is heavy, lung heavily reaches viable count to be provided in infecting the back.All the other mices are divided into 5 groups at random, 6 every group.And in infecting back beginning in the 2nd day administration, the blank group: 0.5% Carboxymethyl cellulose sodium (CMC), INH organizes (negative control group): 25mg/kg, and administration is 5 times weekly; CLF-1 group: 20mg/kg, administration is 5 times weekly; CLF-2 group: 10mg/kg, administration is 5 times weekly; CLF-3 group: 20mg/kg, administration is 2 times weekly; Isoniazid and clofazimine are all used 0.5%CMC and are made the suspension oral gavage administration, are administered to infect back 30d.Next day after last 1 administration, each group mice is put to death, carry out mice spleen, lung count plate.Count plate method: record mice body weight, dissect down the sterile working, get spleen, lung homogenate respectively, the adding normal saline is made and is organized suspension, that gets mice spleen, lung respectively organizes 10 times of dilutions of suspension series, get 0.1ml and be inoculated in modified Russell medium, 3 of each concentration inoculations of each sample cultivated for 4 weeks for 37 ℃.Observe the bacterial growth situation, calculate viable count (CFU).
(3) statistical procedures: data are represented with X ± S, adopt SPSS11.0 software, relatively adopt one factor analysis of variance between group, the LSD method of analysis of variance, and there is statistical significance P＜0.01 for difference.
4, experimental result
(1) minimum inhibitory concentration result
Clofazimine is to mycobacterium tuberculosis H
37R
VMIC be 0.12-0.24 μ g/ml; The MIC of isoniazid and rifampicin is respectively 0.025,0.05 μ g/ml; Clofazimine is 0.12-1.92 μ g/ml to the MIC scope of 30 strain substance of medicines-resistant branched tubercle bacillus clinical separation strains, and concrete data see Table 1.
Table 1 clofazimine is to the MIC (μ g/ml) of 30 substance of medicines-resistant branched tubercle bacillus clinical separation strains
(2) mice tuberculotherapy experimental result
1. the painted situation of mouse skin mucosa: treatment 7d left and right sides CLF-1 group mice ears and breast abdominal part fur begin to occur pale red, treatment 30d when finishing experiment the CLF-1 group (accumulated dose: 400mg/kg), the CLF-2 group (accumulated dose: 200mg/kg) and the CLF-3 group (accumulated dose: 160mg/kg) ears and the dyeing of breast abdominal part fur all appear in mice, and CLF-1 is the most obvious.The organ in the visible 3 groups of mice breasts of when dissected, abdominal cavity is painted, and the CLF-1 group is the most obvious.Death does not appear in mice during whole infection and the treatment.
2. the heavy and heavy situation of lung of body weight, spleen: the 2nd day of mouse infection, average weight be (20.88 ± 0.17) g, average spleen heavy (0.07 ± 0.01), heavy (0.15 ± 0.05) g of average lung, the heavy index 0.003 ± 0.002 of spleen, lung weighs index 0.0070.002.The mice body weight of not treatment group, spleen weight, lung heavily are respectively (24.09 ± 1.84) g, (0.46 ± 0.07) g, (0.24 ± 0.02) g behind the infection 30d.The heavy index of the heavy exponential sum lung of spleen is respectively 0.019 ± 0.002 and 0.010 ± 0.001, all be significantly increased, the mice body weight and the blank group of each treatment group do not have significant difference, but, lung heavy at spleen heavily reaches on the heavy index of spleen, the heavy index of lung and all is lower than the blank group, (the F value is respectively 46.64,27.57,58.97,34.56 to have statistical significance, p＜0.01, concrete data see Table 2.
Table 2 tuberculosis model mice treatment 30d respectively organizes body weight, spleen is heavy and the heavy situation of lung (X ± S)
Annotate:
#P＜0.01 is compared with the blank group
3. count plate situation: the 2nd day of infection, the full spleen viable count of mice is (5.61 ± 0.14) lgCFU, infects 30d and is increased to (7.14 ± 0.07) lgCFU.INH group spleen viable count is than the low 3.56lgCFU of blank group, and the CLF-1 group is hanged down 2.25lgCFU, and all low 1.57lgCFU of CLF-2 group and CLF-3 group.Each treatment group is compared difference and is had statistical significance (F=130.58, p＜0.01) with the blank group.Concrete data see Table 3.Infect the 2nd day, the full lung viable count of mice was (5.24 ± 0.23) log
10CFU infects 30d and increases to (8.07 ± 0.01) lgCFU.INH group lung viable count is than the low 4.68lgCFU of blank group, and the CLF-1 group is hanged down 2.92lgCFU.The low 1.78lgCFU of CLF-2 group, the low 1.39lgCFU of CLF-3 group.Each treatment group is compared difference and is had statistical significance (F=74.09, p＜0.01) with the blank group.Concrete data see Table 3
The count plate situation (lgCFU) of each group of table 3 tuberculosis model mice treatment 30d
Annotate:
△P＜0.01 is compared with the blank group
5, experiment conclusion
The experiment in vitro result shows that clofazimine has strong vitro antibacterial activity to the substance of medicines-resistant branched tubercle bacillus of mycobacterium tuberculosis type strain and anti-isoniazid and rifampicin.Its mechanism of action mainly is interfere RNA metabolism and energy metabolism, is difficult for producing drug resistance, does not have crossing drug resistant with existing antituberculotics, does not have intrinsic interaction with cytochrome P 450 enzymes.
Show that in mice tuberculotherapy model clofazimine can reduce 1.8-2.9lgCFU with the mycobacterium tuberculosis in the mice lungs, reduces 1.5-2.5lgCFU in the spleen, show to have the interior tuberculosis effect of body preferably.
Experimental example 2 clinical experimental datas
Be selected into 25 tuberculosis patients, allow it regularly take the clofazimine soft gelatin capsule, the results are shown in Table 4.
Table 4 Drug therapy of the present invention clinical experimental data lungy
The result shows, it is nearly 96% that medicine clofazimine of the present invention is treated effective percentage lungy and obvious effective rate, illustrates that clofazimine has treatment effect lungy.
Following embodiment all can realize the effect of above-mentioned experimental example.
The specific embodiment
Embodiment 1: the clofazimine soft gelatin capsule
Clofazimine adds the refining of edible vegetable oil and grinds to form fine powder and adjust concentration, and suspendible is made.Aplanatic (the C of chloride method
27H
22Cl
2N
4) be 90.0%～110.0% of labelled amount.Oral, a 50～100mg, 1-3 time on the one, treatment tuberculosis.
Embodiment 2: the clofazimine sheet
Add conventional adjuvant and make tablet according to a conventional method, oral, a 50～100mg, 1-3 time on the one, treatment tuberculosis.
Embodiment 3: the clofazimine granule
Add conventional adjuvant and make granule according to a conventional method, oral, a 50～100mg, 1-3 time on the one, treatment tuberculosis.
Claims (1)
1, the application of clofazimine in preparation treatment tuberculosis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910131770A CN101658523A (en) | 2008-04-01 | 2009-04-01 | New application of clofazimine for curing tuberculosis |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810103174 | 2008-04-01 | ||
| CN200810103174.5 | 2008-04-01 | ||
| CN200910131770A CN101658523A (en) | 2008-04-01 | 2009-04-01 | New application of clofazimine for curing tuberculosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110379091 Division CN102406643B (en) | 2008-04-01 | 2009-04-01 | Medical application of clofazimine in tuberculosis treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101658523A true CN101658523A (en) | 2010-03-03 |
Family
ID=41786924
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110379091 Active CN102406643B (en) | 2008-04-01 | 2009-04-01 | Medical application of clofazimine in tuberculosis treatment |
| CN200910131770A Pending CN101658523A (en) | 2008-04-01 | 2009-04-01 | New application of clofazimine for curing tuberculosis |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110379091 Active CN102406643B (en) | 2008-04-01 | 2009-04-01 | Medical application of clofazimine in tuberculosis treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102406643B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111728973A (en) * | 2020-05-27 | 2020-10-02 | 中国医学科学院病原生物学研究所 | Medicine for resisting novel coronavirus SARS-CoV-2 and its application |
| CN114344273A (en) * | 2021-12-08 | 2022-04-15 | 余述南 | A soft capsule for treating tuberculosis and multi-drug resistant tuberculosis |
| CN114376979A (en) * | 2021-12-08 | 2022-04-22 | 余述南 | Preparation method of soft capsule for treating tuberculosis and multi-drug resistant tuberculosis |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2553310C2 (en) * | 2013-05-07 | 2015-06-10 | Общество с ограниченной ответственностью "ЭДВАНСД ТРЕЙДИНГ" | Capsular form of clofazimine |
| CN114507189A (en) * | 2021-12-08 | 2022-05-17 | 余述南 | Chemically synthesized bulk drug and application thereof in treating tuberculosis and drug-resistant tuberculosis |
-
2009
- 2009-04-01 CN CN 201110379091 patent/CN102406643B/en active Active
- 2009-04-01 CN CN200910131770A patent/CN101658523A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111728973A (en) * | 2020-05-27 | 2020-10-02 | 中国医学科学院病原生物学研究所 | Medicine for resisting novel coronavirus SARS-CoV-2 and its application |
| CN114344273A (en) * | 2021-12-08 | 2022-04-15 | 余述南 | A soft capsule for treating tuberculosis and multi-drug resistant tuberculosis |
| CN114376979A (en) * | 2021-12-08 | 2022-04-22 | 余述南 | Preparation method of soft capsule for treating tuberculosis and multi-drug resistant tuberculosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102406643A (en) | 2012-04-11 |
| CN102406643B (en) | 2013-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rubinstein et al. | Tissue penetration of amphotericin B in Candida endocarditis | |
| CN102406643B (en) | Medical application of clofazimine in tuberculosis treatment | |
| CN103665080A (en) | Triterpenoid compounds and application thereof in diabetes treatment drugs | |
| IT202000003233A1 (en) | BACTERIAL STRAIN AND ITS MEDICAL USES | |
| US20070248619A1 (en) | New pharmaceutical composition from natural materials for regulating immunity, its preparation method and use | |
| CN101890030A (en) | Composite capable of preventing bacteria, viruses, oxidation and pigment deposition | |
| WO2006104292A1 (en) | Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts | |
| Vivino et al. | Sulfonamide-Resistant Strains of Staphylococci: Clinical Significance. | |
| CN111544451A (en) | Composition for resisting helicobacter pylori and application thereof | |
| CN101474173B (en) | Application of cumarin coumpound Murraya jasminorage ketone in preparing anti-tumor medicament | |
| CN107320471B (en) | Cycloserine pharmaceutical composition for treating tuberculosis and application thereof | |
| US20130149393A1 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN108113990B (en) | A kind of pharmaceutical composition for treating urinary tract infections | |
| CN104083361B (en) | A kind of Chinese medicine composition for the preparation of anti-candida medicine | |
| WO2006053487A1 (en) | The use of vegetable anthraquinone derivatives and vegetable polysaccharides for treating human immunodeficiency virus (hiv) | |
| White et al. | Bacterial contamination in some nonsterile antibiotic drugs | |
| CN101863876B (en) | Fluoroquinolone comprising 7-(3-amino-4-oximido)-1-piperidyl substitutional group and application of composition thereof | |
| CN102470141A (en) | Glycyrrhizin as restorative agent for antimicrobial peptide production ability | |
| Lazarus et al. | Post-craniotomy wound infection caused by Pseudallescheria boydii: case report | |
| CN104083360B (en) | A kind of Chinese medicine composition for the preparation of anti-aspergillosis medicine | |
| CN112245433B (en) | Application of ectoine substances in preparation of medicine for preventing and treating cerebral arterial thrombosis | |
| CN102988765A (en) | Usage of rhizoma bletillae ethyl acetate extractive | |
| CN115487202B (en) | Application of fidaxomicin in preparation of medicines for resisting nocardia infection | |
| CN104212723B (en) | One strain Herba Artemisiae Japonicae Nei Shengyouwei can intend dish stey and application thereof | |
| Olorode et al. | Efficacy of Nigerian Local Honey on Pseudomonas Aeruginosa from Infected Wound among Genders in Federal Medical Center, Bayelsa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100303 |